Latest News
Pharmacist's Application to Practice: Mirdametinib
Ramsey Shane, PharmD, MPH, PGY1 Pharmacy Resident, and Rebecca Pokorny, PharmD, BCPS, BCOP, Clinical Pharmacist Specialist Neuro-Oncology - both from Vanderbilt University Medical Center, Nashville, TN - write about mirdametinib (Gomekli).
Pharmacist's Application to Practice: Ensartinib
Savannah Young, PharmD, PGY1 Pharmacy Resident, from Sarasota Memorial Hospital, Sarasota, FL, and Kiera Roubal, PharmD, BCOP, Clinical Oncology Pharmacist Specialist, from Medical University of South Carolina, Charleston, SC, write about ensartinib.
Pharmacist's Application to Practice: Cosibelimab-ipdl
Nathan Schieldt, PharmD, PGY2 Oncology Resident; William Morrissey, PharmD, PGY2 Oncology Resident; and Anna Clennon, PharmD, BCOP Clinical Pharmacist - all from Aurora St. Luke's Medical Center, Milwaukee, WI - write about cosibelimab-ipdl.
Pharmacist's Application to Practice: Zenocutuzumab-zbco
Allen Barry, MBA, PharmD Candidate Class of 2025, and Alisha Vora, PharmD, BCOP, CPP, Clinical Pharmacist Practitioner, Gastrointestinal Medical Oncology - both from the University of North Carolina, Chapel Hill, NC - write about zenocutuzumab-zbco.
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
